Interviews

Late-breaking phase 2 immunoPRISM trial data show teclistamab superior to Len/Dex in high-risk smoldering myeloma, with higher CR rates and PFS.

Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis.

In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.

Replacing chemotherapy with blinatumomab improved event-free survival and reduced toxicity in high-risk pediatric ALL, data show.

The phase 3 frontMIND trial showed tafasitamab plus lenalidomide with R-CHOP reduced risk of disease progression or death in high-risk DLBCL.

ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.

Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

Post-AKI care requires tiered monitoring and medication holds, yet awareness gaps persist among patients and clinicians, said Thai Dang, MD.

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

ADA 2026 spotlighted triple incretin therapy, intensive LDL lowering, and the equity gaps that keep advances from reaching all patients.

SC isatuximab via OBI earned EU approval in multiple myeloma, showing less than 1% IRR rates, strong reliability, and potential for at-home use.

Shannon L. Maude, MD, PhD, highlighted promising long-term disease-free survival and MRD negativity with tisagenleucel in high-risk pediatric ALL.

Ziftomenib plus intensive chemotherapy produced high response and MRD negativity rates with manageable safety in newly diagnosed AML.

Long-term LUNA3 data showed rilzabrutinib delivered durable platelet responses, reduced bleeding and fatigue, and maintained safety in ITP.

Sandra Chaparro, MD, discusses using obesity medications in patients with heart failure.

Nancy Lin, MD, explains how an AI model compares with genomic classifiers in HR+/HER2- early breast cancer, with implications for cost and access.

Re-engagement strategies for hepatitis B show promise in the US, but data gaps and structural barriers are slowing progress toward WHO elimination targets.

Bridget Vazquez, PsyD, breaks down how cancer-related PTSD manifests, why it goes unrecognized, and what patients, caregivers, and clinicians can do.

New ADA 2026 data show diabetic ketoacidosis hospitalizations rising 24%, driven by poor ketone monitoring and symptom recognition gaps across all ages.

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option.

By controlling for ovarian suppression, OPTIMA shows Prosigna works equally well in pre and postmenopausal high-risk early breast cancer.

Research from Samuel Shangwu Wu, PhD, presented as an ADA Presidents' Select Abstract, proposes a better way to measure beta-cell preservation.

Kerry Rogers, MD, examines the underemphasized BTK inhibitor adverse effects that quietly erode patient quality of life—and what to do about them.

Anne Komé, PharmD, explains that diabetes drug development is shifting to concurrent testing of metabolic effects.

ADA 2026 research showed how oral ketones, irisin, and SGLT2 inhibitors may reveal new metabolic pathways beyond glucose control.

Phase 3 data show survodutide normalized liver fat in 61% of patients with MASLD while reducing weight, visceral fat, and metabolic risk factors.

ADA 2026 data show survodutide cut visceral fat by 34% and liver fat by 63%, suggesting metabolic benefits beyond weight loss in phase 3 trials.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.